Abstract A 61-year-old Japanese woman was diagnosed with FIGO Stage IB endometrioid cancer (EC) combined with large cell neuroendocrine carcinoma (LCNEC). Metastasis to the lymph nodes in the right bronchopulmonary area, mediastinum and brain were also identified. The patient eventually developed pleuritis and pericarditis carcinomatosa, and died of cancer at 51 months after surgery. Because gene aberrations in uterine neuroendocrine carcinoma are still not well understood, we examined alterations in the mutational hotspots of 50 selected cancerassociated genes. The EC and LCNEC components shared identical alterations in PTEN, PIK3CA and FGFR3. Both the EC and LCNEC components had heterozygous SBSs on CTNNB1 but at different codons (G34R in EC, and T41A in LCNEC). The altered gene signature raised a possibility that the EC and LCNEC components were derived from a common precursor lesion. The LCNEC independently obtained a significant CTNNB1 mutation and the lymph node metastasis originated from this component. Because the LCNEC component seemed to bring about the aggressive course of the disease and defined the patient outcome, further investigations are needed to elucidate the mechanism of NE carcinoma development in the endometrium.
Introduction
Neuroendocrine (NE) carcinomas of the female genital tract are aggressive and uncommon tumors. They usually involve the cervix and ovary, and are very rarely observed in the endometrium. The overwhelming majority of endometrial NE carcinoma cases are of the conventional small cell type (up to 80 cases), and only 14 cases of large cell neuroendocrine carcinoma (LCNEC) of the endometrium have been reported in the literature. The majority of LCNEC develop in the lung. Both small cell lung cancer (SCLC) and LCNEC are considered as high-grade NE carcinoma and share several gene expression profiles [1] . However, it is controversial to consider them as a single entity when considering treatment options, and morphological and phenotypical differences between the two have been investigated [2, 3] . Here we report a case of combined LCNEC and endometrioid carcinoma (EC). To elucidate the origin of LCNEC, which determines patient outcome and death, we examined somatic gene alterations in this case. According to the mutational signatures, we discuss the origin of the LCNEC.
Case report Clinical presentation
A 61-year-old Japanese woman (gravida 4, para 4) visited our hospital because of abnormal uterine bleeding for 1 year. Magnetic resonance imaging (MRI) showed a heterogeneously enhanced mass in the endometrium with suspected invasion to more than half of the myometrium on T2-weighted imaging. The patient was diagnosed preoperatively to be grade 1 (G1) EC corresponding to International Federation of Gynecology and Obstetrics (FIGO) stage IB. The patient underwent a modified radical hysterectomy with bilateral salpingo-oophorectomy, omentectomy, and pelvic lymphadenectomy.
Grossly, a polypoid tumor (3.5 9 2.5 9 2.1 cm 3 ) was identified in the uterine corpus. Histologically, the majority of the tumor tissue was revealed to be G1 EC but associated with a solid area (Fig. 1a, b) . The EC component accounted for 75 % of the tumor, while the solid LCNEC area accounted for 25 % of it. The solid component contained extensive geographic necrosis (Fig. 1c) and consisted of generally monotonous growth of medium-to large-sized atypical cells with occasional trabecular patterns and a Rosette-like cell arrangement (Fig. 1d, e) . The cells contained hyperchromatic nuclei with frequent mitotic figures. The tumor cells were positive for synaptophysin (Fig. 1f) , NSE and p53, and negative for chromogranin, estrogen receptor (ER) and CD56. Synaptophysin was positive in 20 % of the LCNEC part, and NSE was positive in 50 % of it. Both were negative in the EC part.
As controls, we used normal pancreas and colon tissue in the immunohistochemical analysis. The overall features were consistent with high-grade NE carcinoma of large cell type. Finally, we diagnosed the tumor to be FIGO Stage IB (pT1bN0M0), combined with G1 EC and LCNEC. The EC component accounted for 75 % of the tumor tissue and was identified in a region away from the cervix, while the LCNEC component accounted for 25 % of the tumor and was situated in an area close to the cervix.
Postoperative chemotherapy was refused by the patient. Serum NSE was elevated at 21 months after surgery, and computed tomography (CT) followed by a biopsy of the lymph node in the right mediastinum diagnosed metastasis from the uterine carcinoma. Synaptophysin was positive in 40 % of tumor cells. Palliative irradiation to the metastatic lymph nodes (LN) was performed. Thereafter, the patient developed brain metastasis, pleuritis and pericarditis carcinomatosa, and died of cancer at 51 months after surgery.
Gene mutations in the EC and LCNEC components
To investigate the histopathogenesis of the LCNEC component, we examined gene alterations in the mutation hotspots of 50 selected cancer-associated genes with the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies Co., Carlsbad, CA). The mutation hotspots and interrogated 50 genes can be found at the following link: http://www. thermofisher.com/. Briefly, DNA was extracted from thinly sliced sections of formalin-fixed and paraffin-embedded tissues obtained from G1 EC, and LCNEC components, non-neoplastic endometrium (EM) and the metastatic lymph node, and subjected to the sequencing analyses. The precise methods of experiments are provided in the Supplementary Methods.
The EC and LCNEC components of the uterus shared identical alterations in PTEN, PIK3CA and FGFR3. The PTEN alteration was an almost homozygous missense single-base substitution (SBS), resulting in R130G (CGA to GGA). Similarly, PIK3CA was heterozygous for a missense SBS resulting in R88Q (CGA to CAA), and FGFR3 was heterozygous for a single-base deletion (c.2383delC), resulting in a frameshift that deleted the 11 C-terminal amino acids, instead of adding a novel polypeptide consisting of 23 amino acids (p.P799R fsX23, based on NM_000142 FGFR3 sequence). Only the EC contained another missense heterozygous SBS on FGFR3, resulting in A376T (GCA to ACA). Both the EC and LCNEC components had heterozygous SBSs in CTNNB1, but the EC contained G34R (GGA to AGA) while the LCNEC contained T41A (ACC to GCC). In addition, the EC contained a different T41A (ACC to ATC) mutation in CTNNB1 with a low allele frequency of less than 10 %. No gene alterations were identified in non-neoplastic endometrial tissue in these analyses. The metastatic LN completely shared mutations with the LCNEC, that is, the CTNNB1 T41A mutation was ACC to GCC, not ACC to ATC. The mutational profiles of tumors are summarized in Table 1 and are detailed in Supplementary Table 1 .
Discussion
Neuroendocrine carcinomas of the female genital tract are extremely rare, and comprise fewer than 2 % of gynecological cancers. They include carcinoid tumors, small cell NE carcinoma and LCNEC. NE features should be confirmed by positive immunohistochemical markers, such as chromogranin, synaptophysin, CD56 and NSE [4] . LCNECs, especially found in combination with other histologic types, have to be differentially diagnosed against dedifferentiated carcinomas. LCNECs are recognized by their arrangement in well demarcated nests, presence of trabeculae or cords with peripheral palisading, and positivity for staining of a neuroendocrine marker in more than 10 % of cells, as evident in this case. In dedifferentiated carcinomas, associations between cells are often accompanied by inflammatory cells that are loosely alveolar in structure, but in this case, cells were well clustered with few inflammatory cells. To the best of our knowledge, only 15 cases of endometrial LCNEC have been reported to date, including the present case (Table 2 ) [4] [5] [6] [7] [8] [9] [10] [11] [12] . Nine cases were pure LCNEC, and the remaining cases were associated with other types of tumors including EC (four cases), small cell NE carcinoma together with EC (one case) and papillary serous carcinoma (one case). Although the polypoid feature in small cell carcinomas of the endometrium is reported to be a reliable predictor of survival, this is not the case for LCNEC [7] . Although no established treatment has been demonstrated for LCNEC of the uterine body, the majority of cases are administered multimodality therapy. With regard to chemotherapy, patients generally received six cycles of cisplatin and etoposide [11] . In the present study, the EC and LCNEC components shared identical alterations in PTEN, PIK3CA and FGFR3, although the EC component contained an additional missense mutation in FGFR3. The shared PTEN R130G mutation is an inactivating alteration of the encoded product. PIK3CA encodes the p110a catalytic subunit of phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3Ka). The shared PIK3CA R88Q is a gain-of-function mutation located in the adaptor-binding domain (ABD) of PI3Ka. Although more than 80 % of PIK3CA mutations are found in its helical and kinase domains in other tumors, EC is reported to have additional mutation hotspots including the ABD, as observed in the present case [13] . Moreover, in the same PI3 K-AKT pathway, simultaneous inactivation of PTEN and activation of PI3Ka are frequently observed in approximately 40 % of EC cases [13] . The heterozygous FGFR3 p.P798R fsX23 mutation was also associated with the both histological components with uncertain significance at present. However, CTNNB1, which encodes b1-catenin, a cadherin-associated membrane protein, showed an interesting mutation profile in the present case, whereby the EC contained a heterozygous G34R mutation while the LCNEC contained another heterozygous T41A mutation. Both of the missense mutations were previously reported in EC [14] but not in NE carcinomas (COSMIC database). T41A mutation is the most frequent CTNNB1 mutation (940 out of 5579 (17 %) CTNNB1 missense mutations, COSMIC) and its biological significance has been confirmed, while G34R is a rare mutation of less than 2 % and the significance of glycine (G) residue alteration to arginine TAH total abdominal hysterectomy; BSO bilateral salpingo-oophorectomy; OMY omentectomy; PPALND pelvic and paraaortic lymph node dissection; PLND pelvic and node dissection; RH radical hysterectomy; mRH modified radical hysterectomy; APPY appendectomy; RT radiotherapy; Cis Cisplatin; Eto etoposide; NFT no further treatment; Carbo carboplatin; Oct octreotide; Doxil pegylated doxorubicin; Iri irinotecan; DOD dead of disease; AWD alive with disease; M months (R) is uncertain. Activation of b1-catenin via A41T in the LCNEC could be stronger than that with G34R. PTEN inactivation was identified in more than 80 % of EC cases with the highest rates [15] and is considered an early event in the tumorigenesis observed in endometrial intraepithelial neoplasia (EIN) or in earlier latent precancerous lesions [16] . Additional hormonal selection, microsatellite instability or mutational activation of KRAS or b1-catenin are known events occurring in the stepwise progression to EC [17] . One could speculate that both the EC and LCNEC components of the present case developed according to the stepwise EC tumorigenesis including the common PTEN inactivation. Although the common PIK3CA R88Q mutation was shared by the EC and LCNEC components, the CTNNB1 mutation was completely different between them. There is a possibility that the independent CTNNB1 mutation determined the fate of the precursor lesion, but further analyses are needed to confirm this speculation. The mutational profile of the endometrial LCNEC is not yet known, but the profile of pulmonary LCNEC has been precisely investigated [18] . The profile is generally divided into small cell lung carcinoma (SCLC)-like and non-SCLC-like types. The SCLClike type is characterized by simultaneous TP53 and RB1 inactivation. The non-SCLC type shows frequent TP53 mutations without RB1 mutation, instead of the characteristic mutations found in adenocarcinoma, squamous cell carcinoma or other types of tumors. Frequently mutated genes in pulmonary LCNEC are TP53, RB1, KRAS, STK11, KEAP1, PTPRT, NKX2-1, NTRK3, NOTCH1, NOTCH4 and EPHA5. Among these genes, TP53, RB1, KRAS, STK11 and NOTCH1 were also examined in the present study, but no mutations were found in these genes. The cue for the development of endometrial LCNEC may be different from the pulmonary counterpart. The common FGFR3 frameshift mutation was shared between LCNEC and EC in the present case, but the significance is unknown. The metastatic lymph node of the bronchopulmonary region seemed to originate from the LCNEC component because of the mutational profile.
In summary, the mutational signature in this study raised a possibility that the EC and LCNEC components were derived from a common precursor lesion but further analyses are required to clarify this. Investigations of gene mutations in multiple cases of endometrial NE carcinoma are needed to elucidate the mechanisms involved in the development of this highly malignant histological subtype, and to identify targets for effective personalized treatments.
